Abstract

Prostate cancer (PCa) is characterized by pronounced molecular heterogeneity, complicating risk stratification and 
therapeutic decision-making. Recent advances in single-cell and spatial omics technologies enable high-resolution 
profiling of tumor and microenvironmental heterogeneity, offering unprecedented insights into prostate cancer 
biology. Single-cell omics captures transcriptomic, epigenomic, and proteomic information at the individual cell 
level, while spatial omics preserves tissue architecture and intercellular context. Translating these technologies 
into clinical practice requires robust biomarker discovery, analytical and clinical validation, regulatory clearance, 
and evidence of clinical utility. Real-world adoption is constrained by technical and infrastructural barriers, high 
costs, workforce limitations, data-management challenges, and equity considerations, particularly for 
underrepresented populations disproportionately affected by prostate cancer. Phased implementation strategies, 
collaborative partnerships, and quality-assurance frameworks can facilitate clinical integration while promoting 
equitable access. Future research should prioritize diverse population representation, standardized methodologies, 
and innovative translational frameworks to fully harness single-cell and spatial omics for precise prostate cancer 
stratification and personalized management.